Amid intense concern that low-income countries lack access to Covid-19 vaccines, Moderna (MRNA) announced plans to build a manufacturing plant in Africa that can produce up to 500 million doses each year for different diseases in a bid to combat the pandemic and other illnesses on a wider scale.
But the move was quickly panned by patient advocates who saw a public relations gambit for thwarting efforts to convince drug makers to share technology, which could be used by other companies to boost vaccine production for global distribution more quickly.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
